Pharmaceutical

STAT+: PTC Therapeutics’s PKU drug succeeds in trial, b...

Biotech firm PTC Therapeutics said Wednesday that its drug for phenylketonuria, ...

STAT+: A new startup looks to turn the workhorse of gen...

“This is already the way your body fights cancer. We're basically just superchar...

Opinion: How ‘Lessons From the Covid War’ falls short

As with our pandemic response itself, "Lessons from the Covid War" goes wrong mo...

Opinion: Do chatbots have more time to be empathetic th...

Oncologist Jennifer Lycette is doubtful that AI could replace that personal conn...

Opinion: New draft recommendations for mammograms take ...

All patients should have the opportunity to understand mammography’s limitations...

Opinion: Starting breast cancer screening at 40 saved m...

The decision to lower the recommended age for breast cancer screening back to 40...

STAT+: Biotech and pharma execs wrestle with the ‘night...

Many drugmakers are still in the earliest stages of incorporating digital endpoi...

Depression hits new high among Americans, per survey

More than a quarter of American adults are depressed, a 10% surge from nearly a ...

STAT+: FTC move to block the Amgen-Horizon deal highlig...

The FTC's move to block the Amgen-Horizon deal highlights concerns over negotiat...

STAT+: AI leaders issue a plea to Congress: Regulate us...

“Regulatory intervention by governments will be critical to mitigate the risks o...

Pfizer RSV vaccine seen as effective against severe dis...

An experimental RSV vaccine developed by Pfizer to protect infants — by vaccinat...

Telehealth company Included Health ventures into home care

In the latest edition of STAT Health Tech: General Catalyst and a16z make a big ...

Phase I completion of Sanofi’s vWD therapy demonstrates...

Sanofi’s announcement provides a more positive outlook for the vWD market as it ...

Juno Pharmaceuticals buys Omega Laboratories

The merged entity represents one of the biggest specialist generic injectable op...

Nuvectis Pharma receives IND approval from FDA for NXP900

NXP900 is a new inhibitor of the SRC family of kinases with low nanomolar effect...

Gilead and Arcus Biosciences expand research collaborat...

Arcus will commence research programmes against up to four targets for inflammat...